<p>Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis</p>

Abstract

Objective: The EXTREME clinical trial revealed that cetuximab plus chemotherapy improved the overall survival time of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) versus chemotherapy alone. The current study examined the cost-effectiveness of cetuximab plus chemotherapy compared with chemotherapy alone in HNSCC patients from the perspective of China. Materials and Methods: A partitioned survival model was implemented for R/M HNSCC patients. Survival information was derived from the CHANGE-2 trial. The model was designed as a ten-year time horizon, a 3-week cycle, and a 3% discount rate for costs and utilities. An incremental cost-effectiveness ratio (ICER) value is less than $30,201/qualityadjusted life-year (QALY) was considered cost-effective in China. We analyzed the uncertainty by performing one-way and probabilistic sensitivity analyses. Results: In the base-case analysis, we found that the ICER of cetuximab plus chemotherapy compared with chemotherapy alone is $172,702/QALY. The results of one-way sensitivity analysis and probabilistic analysis showed that the fluctuations of each variable in its ranges do not cause ICERs to reach acceptable thresholds. Conclusion: The current observations suggested that treatment with cetuximab plus chemotherapy is not a cost-effective strategy for R/M HNSCC patients in China at a $30,201 willingness to pay threshold.

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

“…The Chinese Yuan was converted into USD using the following exchange formula: 1US $ = CNY 6.4. The costs were calculated for medicines, administration ( Lang et al, 2020 ), tumor imaging ( Yang et al, 2020 ), laboratory tests ( Yang et al, 2020 ), BSC ( Xin et al, 2020 ), and management of severe AEs (assuming that Aes emerged only once in the PFS and PD states) ( Guan et al, 2019 ; Lang and Dong, 2020 ; Lang et al, 2020 ; Li et al, 2020 ) ( Table 1 ). Grades 3 to 4 Aes with an incidence rate of ≥5% in either group or with significantly different rates between groups were estimated in the calculation.…”

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

“…Grade 1 and 2 AEs could be well-managed, the costs of management were not considered. The costs of managing grade 3-5 AEs were sourced from previously published economic studies (21,22). All costs reported for years prior to 2020 were updated to 2020 US dollars (US$) using the health care services component of Chinese Consumer Price Index.…”

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

“…Head and neck squamous cell carcinomas (HNSCC) represent the sixth most common type of cancer with 830,000 new cases and around 430,000 deaths each year worldwide ( 1 ). HNSCC is a spectrum of malignancies arising from the mucosal lining of the upper aerodigestive tract, with different localizations (concerning larynx, hypopharynx, oropharynx, nasopharynx, oral and nasal cavities, and paranasal sinuses) ( 2 , 3 ).…”